Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study.

ABSTRACT:

Purpose

We report the 2-year outcomes of intravitreal aflibercept (IVA) for exudative age-related macular degeneration (AMD) with good visual acuity (VA) and examine the baseline factors associated with good visual outcome.

Materials and methods

This multicenter, prospective study evaluated 39 eyes (39 AMD patients) enrolled from August 2013 to August 2014 at 12 and 24 months. Only patients with initial best-corrected VA (BCVA) >0.3 logarithm of the minimum angle of resolution (20/40 Snellen) were eligible. Three consecutive monthly IVA injections were followed by 2 monthly injections for 12 months. Thereafter, patients received injections on a treat- and-extend regimen for up to 24 months. Outcome measures included BCVA and central macular thickness (CMT) at 12 and 24 month

SUBMITTER: Sakamoto S 

PROVIDER: S-EPMC6022819 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature